Opin vísindi

Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits

Show simple item record

dc.contributor Háskóli Íslands
dc.contributor University of Iceland
dc.contributor.author Drobnjak, Tijana
dc.contributor.author Meiri, Hamutal
dc.contributor.author Mandalá, Maurizio
dc.contributor.author Huppertz, Berthold
dc.contributor.author Gizurarson, Sveinbjorn
dc.date.accessioned 2018-09-25T13:45:33Z
dc.date.available 2018-09-25T13:45:33Z
dc.date.issued 2018-07
dc.identifier.issn 1177-8881
dc.identifier.uri https://hdl.handle.net/20.500.11815/856
dc.description.abstract Introduction: Human placental protein 13 (PP13) is a galectin predominantly expressed by the placenta. Low serum concentrations of PP13 in early pregnancy indicate a higher risk of developing preeclampsia. Methods: The pharmacokinetic disposition and bioavailability of PP13 were determined by single intravenous and subcutaneous administration to 12 healthy New Zealand White rabbits. The serum pharmacokinetic values were determined by enzyme-linked immunosorbent assay, and are best described by a two-compartment model. Results: Both volume of distribution and the area under the curve were dose dependent for the intravenous group (p < 0.01). PP13 elimination half-life was also found to be different between the groups (p < 0.01). The bioavailability of PP13 following subcutaneous administration was found to be 57%. Conclusion: This study shows that the concentration of total PP13 released into the maternal circulation during pregnancy might be much higher than previously estimated.
dc.description.sponsorship The authors thank Hy Laboratories for providing PP13 to this study through support provided by the European Union through the ASPRE project (# 601852). This study was mainly sponsored by Hananjaehf and the Icelandic Research Fund (Rannis; grant number 163403-052).
dc.format.extent 1977-1983
dc.language.iso en
dc.publisher Dove Medical Press Ltd.
dc.relation.ispartofseries Drug Design, Development and Therapy;12
dc.rights info:eu-repo/semantics/openAccess
dc.subject Pharmacology
dc.subject Drug Discovery
dc.subject Pharmaceutical Science
dc.subject Lyfjafræði
dc.subject Lyfjaefnafræði
dc.subject Lyfhrifafræði
dc.title Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits
dc.type info:eu-repo/semantics/article
dcterms.license This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
dc.description.version Peer Reviewed
dc.identifier.journal Drug Design, Development and Therapy
dc.identifier.doi 10.2147/DDDT.S167926
dc.contributor.department Lyfjafræðideild (HÍ)
dc.contributor.department Faculty of Pharmaceutical Sciences (UI)
dc.contributor.school Heilbrigðisvísindasvið (HÍ)
dc.contributor.school School of Health Sciences (UI)

Files in this item

This item appears in the following Collection(s)

Show simple item record